Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer

被引：2
|
作者：
Qiu, M. [1 ]
Wei, G. [1 ]
Leng, W. [1 ]
Cao, P. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, West China Sch Med, Dept Colorectal Canc Ctr, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1815
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
624P
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 50 条
  • [1] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Sharma, Vinod
    Vanidassane, Ilavarasi
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 876 - 876
  • [2] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Roviello, Giandomenico
    D'Angelo, Alberto
    Petrioli, Roberto
    Roviello, Franco
    Cianchi, Fabio
    Nobili, Stefania
    Mini, Enrico
    Lavacchi, Daniele
    TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
  • [3] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Desai, J.
    Yoshino, T.
    Wasan, H.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H. -T.
    Garcia-Alfonso, P.
    Pfeiffer, P.
    Orlov, S.
    Lonardi, S.
    Elez, E.
    Kim, T. -W.
    Schellens, J. H. M.
    Guo, C.
    Krishnan, A.
    Dekervel, J.
    Morris, V.
    Calvo Ferrandiz, A.
    Tarpgaard, L. S.
    Braun, M.
    Gollerkeri, A.
    Keir, C.
    Maharry, K.
    Pickard, M.
    Christy-Bittel, J.
    Anderson, L.
    Sandor, V.
    Tabernero, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1632 - 1643
  • [4] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer Reply
    Kopetz, Scott
    Grothey, Axel
    Tabernero, Josep
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 877 - 878
  • [5] Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 199 - 202
  • [6] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Li, Shuosha
    Hu, Huabin
    Ding, Dong
    Zhu, Youwen
    Huang, Jin
    ADVANCES IN THERAPY, 2021, 38 (03) : 1650 - 1659
  • [7] Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA
    Shuosha Li
    Huabin Hu
    Dong Ding
    Youwen Zhu
    Jin Huang
    Advances in Therapy, 2021, 38 : 1650 - 1659
  • [8] Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer
    Akhoundova, Dilara
    Pietge, Heike
    Hussung, Saskia
    Kiessling, Michael
    Britschgi, Christian
    Zoche, Martin
    Rechsteiner, Markus
    Weber, Achim
    Fritsch, Ralph M.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1082 - 1087
  • [9] Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer
    Stammler, Romain
    Gallois, Claire
    Taieb, Julien
    Duong, Jean-Paul
    Karras, Alexandre
    Thervet, Eric
    Lazareth, Helene
    EUROPEAN JOURNAL OF CANCER, 2021, 147 : 60 - 62
  • [10] BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer
    Owaki, Seira
    Mori, Yoshinori
    Nakai, Shunsuke
    Maeda, Hideki
    Imazu, Mitsuki
    Tomita, Yusaku
    Kanaiwa, Hiroki
    Yamaguchi, Ayana
    Kitagawa, Mika
    Hirano, Atsuyuki
    Kimura, Yoshihide
    Tsuchida, Kenji
    Kataoka, Hiromi
    INTERNAL MEDICINE, 2024, 63 (14) : 1995 - 1999
12345